Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
ORIC Pharmaceuticals, Inc. (ORIC) is a clinical-stage biopharmaceutical company pioneering therapies to combat cancer treatment resistance. This news hub provides investors and researchers with timely updates on clinical developments, strategic partnerships, and scientific breakthroughs in precision oncology.
Access consolidated information about ORIC's progress in developing small molecule inhibitors targeting hormone-dependent cancers and resistant tumor mechanisms. The page serves as a historical archive and current awareness tool for tracking milestones in therapeutic innovation.
Key updates include:
Clinical trial advancements for oral therapies addressing treatment-refractory cancers
Research collaborations leveraging AI-driven drug discovery platforms
Regulatory milestones and FDA designations for novel oncology candidates
Bookmark this page for streamlined monitoring of ORIC's progress in overcoming cancer resistance through targeted therapeutic strategies. Check regularly for verified updates directly tied to the company's public disclosures.
ORIC Pharmaceuticals, a clinical stage oncology company listed on Nasdaq under the ticker ORIC, has announced participation in two key investor conferences in June 2024. The company's management will appear at the Jefferies Global Healthcare Conference on June 5 at 10:30 a.m. ET and the Goldman Sachs 45th Annual Global Healthcare Conference on June 10 at 10:40 a.m. ET. Webcasts of these discussions will be available on the company's website, with replays accessible for 90 days following the events.
ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) reported strong financial results and operational updates for Q1 2024. The company initiated three expansion cohorts for ORIC-114 and presented positive data for ORIC-944 in prostate cancer. Cash and investments stand at $331.5 million, ensuring funding until late 2026.
ORIC Pharmaceuticals, Inc. announced the granting of 14,500 non-qualified stock options and 2,300 restricted stock units to new non-executive employees under the 2022 Inducement Equity Incentive Plan. The grants were approved as inducements to employment and are subject to vesting conditions.
